These peptides target complementary pathways in the gastrointestinal system, making them among the most studied candidates in preclinical gut health research
Ipamorelin activates GHS-R1a through Gq-coupled phospholipase C, increasing IP3 and intracellular calcium, which triggers vesicle fusion and exocytosis
On the contrary, Vos et al reported similar RBC survival in HD ( n = 14) and PD ( n = 5) patients using different laboratory techniques (label loss from RBCs associated with the chromium 51 labeling technique) [266]
Another pivotal mechanism involves the induction of epithelial-mesenchymal transition (EMT), an early event enabling cancer cells to initiate metastasis
Neither of these rationales is without merit, but its worth being precise about what the evidence does and doesnt support
But here's something that might surprise you: GLP-1 isn't just a medication